Cefoperazone + sulbactam


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult: IV/IM Bone and joint infections; Gynaecological infections; Intra-abdominal infections; Respiratory tract infections; Septicaemia; Skin and soft tissue infections; Urinary tract infections; Meningitis Each vial contains cefoperazone (g)/sulbactam (g): 0.5/0.5 or 1/1: Recommended dose: 1 g/1 g to 2 g/2 g. Severe or refractory infections: May increase dose up to 4 g/4 g. All doses are given 12 hourly in equally divided doses via IV inj over 3 minutes, IV infusion over 15-60 minutes or IM. Max dose of sulbactam: 4 g daily. Doses are individualised based on the expected susceptible pathogens, severity and site of infection. Refer to local guidelines on appropriate dosing frequencies and recommendations.
Contraindications
Hypersensitivity to cefoperazone, sulbactam, or other β-lactam antibacterials (e.g. cephalosporin, penicillin).
Special Precautions
Patient with severe biliary obstruction, poor diet, malabsorption states (e.g. cystic fibrosis). Patient on prolonged IV alimentation regimens or receiving anticoagulant therapy. Renal and severe hepatic impairment. Pregnancy and Lactation. Monitoring Parameters Monitor haematologic status (e.g. prothrombin time), renal, and hepatic function as clinically indicated. Perform culture and susceptibility tests; consult local institutional recommendations before treatment initiation due to antibiotic resistance risks.
Adverse Reactions
Significant: Vitamin K deficiency resulting to coagulopathy, overgrowth of nonsusceptible organisms (prolonged use). Blood and lymphatic system disorders: Neutropenia, leucopenia, eosinophilia, thrombocytopenia, hypoprothrombinaemia. Gastrointestinal disorders: Nausea, vomiting, diarrhoea. General disorders and administration site conditions: Pyrexia, chills, infusion site phlebitis, injection site pain. Hepatobiliary disorders: Jaundice. Investigations: Decreased haemoglobin, haematocrit; increased AST, ALT, blood alkaline phosphatase, blood bilirubin. Nervous system disorders: Headache. Renal and urinary disorders: Haematuria. Skin and subcutaneous tissue disorders: Pruritus, urticaria, maculopapular rash. Vascular disorders: Hypotension, vasculitis.
Potentially Fatal: Clostridium difficile-associated diarrhoea, hypersensitivity reactions including anaphylactoid and severe cutaneous adverse reactions (e.g. toxic epidermal necrolysis, Stevens-Johnson syndrome, dermatitis exfoliative); serious haemorrhage.
Drug Interactions
May increase INR with anticoagulants (e.g. warfarin) thereby potentiating the risk for bleeding.
CIMS Class
ATC Classification
J01DD12 - cefoperazone ; Belongs to the class of third-generation cephalosporins. Used in the systemic treatment of infections.
J01CG01 - sulbactam ; Belongs to the class of beta-lactamase inhibitors. Used in the systemic treatment of infections.
Disclaimer: This information is independently developed by CIMS based on cefoperazone + sulbactam from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 CIMS. All rights reserved. Powered by CIMSAsia.com
MORE
LESS
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in